Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of marbofloxacin liquid in China. Welcome to wholesale bulk high quality marbofloxacin liquid for sale here from our factory. Good service and reasonable price are available.
Marbofloxacin liquid is a fluoroquinolone antibacterial drug solution specifically used in veterinary clinical practice. By effectively inhibiting bacterial DNA gyrase, it exhibits broad-spectrum and potent bactericidal activity against various Gram-negative and Gram-positive bacteria. It is mainly used for the treatment of bacterial infections in animals such as cattle, pigs, dogs, and cats, and can effectively deal with common diseases such as respiratory tract, urinary tract, and skin and soft tissue infections.The formulation of this liquid is scientifically designed, usually having good water solubility, and is convenient for administration via drinking water or oral intake, ensuring that the affected animal population accurately takes the dosage and improving treatment compliance and convenience.
However, to avoid drug residues and the emergence of bacterial resistance, it is necessary to strictly follow the withdrawal period regulations and use it under the guidance of veterinarians to ensure food safety from animal sources while safeguarding public health interests.
Our product
Additional information of chemical compound:
Marbofloxacin COA
Antibacterial mechanism
Marbofloxacin liquid is an animal specific fluoroquinolone bactericidal drug that has the advantages of a wide spectrum of bactericidal activity, strong bactericidal activity, few adverse reactions, and long duration. Its bactericidal mechanism is unique, mainly by inhibiting the activity of bacterial topoisomerase.
Bacterial DNA gyrase, also known as type II topoisomerase, is a key enzyme in bacterial DNA replication and transcription processes, with two subunits A and B. Mabofloxacin mainly acts on the A subunit of the enzyme, inhibiting the activity of bacterial DNA gyrase by generating a ternary complex of DNA, topoisomerase, and quinolone drugs. This effect disrupts the normal replication and transcription of bacterial DNA, blocks DNA synthesis, and prevents bacterial cells from dividing and proliferating normally, ultimately leading to bacterial death.
In Gram negative bacteria, DNA gyrase is the main target of mapofloxacin. For example, for most Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and other Escherichia coli, mapofloxacin can effectively inhibit the activity of their DNA gyrase, prevent bacterial DNA replication, and exert a powerful bactericidal effect. Mabofloxacin can also achieve bactericidal effects against Pasteurella multocida by inhibiting its DNA gyrase.
In addition to type II topoisomerase, mapofloxacin also has an inhibitory effect on type IV topoisomerase in bacterial cells. Type IV topoisomerase also plays an important role in bacterial DNA metabolism, and the inhibition of it by mapofloxacin further interferes with the normal physiological functions of bacterial DNA, enhancing its bactericidal effect. This inhibitory effect on multiple topoisomerases makes the bactericidal activity of mapofloxacin more comprehensive and effective against bacteria.
3. bactericidal spectrum and differences from other bactericidal drugs
Mabofloxacin has a broad bactericidal spectrum and is effective against broad-spectrum Gram positive bacteria (especially Staphylococcus), Gram negative bacteria (such as Escherichia coli, Salmonella typhimurium, Campylobacter jejuni, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morgan Stanley, Proteus mirabilis, Shigella spp., Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Klebsiella spp., Haemophilus spp., etc.) and mycoplasma.
Compared with other bactericidal drugs, the bactericidal mechanism of mapofloxacin is different, so the possibility of cross resistance is very small, especially with non fluoroquinolone antibiotics. For example, some pathogenic bacteria that have developed partial resistance to erythromycin, lincomycin, chloramphenicol, doxycycline, and sulfonamide drugs, such as Staphylococcus aureus, are still sensitive to ciprofloxacin. This is because the unique bactericidal mechanism of mapofloxacin allows it to effectively exert its bactericidal effects without being affected by the resistance mechanisms of these drugs.
4. Manifestation of bactericidal effect
Mabofloxacin can rapidly kill bacteria through the above bactericidal mechanism. Sensitive bacteria can cause death within 20-30 minutes after exposure. In clinical application, it can be used to treat a variety of animal infectious diseases caused by sensitive bacteria, such as deep and superficial skin infections, urinary tract infections in dogs, skin and soft tissue infections in cats, acute upper respiratory tract infections, bovine and sheep mastitis, and porcine mastitis uteritis no milk syndrome.
Main Clinical Veterinary Indications
Marbofloxacin liquid is a third-generation fluoroquinolone broad-spectrum bactericidal liquid formulation exclusively for veterinary use. Featuring a broad bactericidal spectrum, potent bactericidal activity, high tissue penetration and favourable tolerability in animals, it is widely applied to treat diverse bacterial infections in dogs and cats. By inhibiting bacterial DNA gyrase and topoisomerase IV, the agent blocks bacterial nucleic acid replication and transcription to achieve rapid bactericidal effects.
It demonstrates high susceptibility against Gram-negative bacteria, selected Gram-positive bacteria and mycoplasmas, making it one of the core anti-infective drugs in small-animal practice. Its clinical indications closely correspond to common bacterial diseases in dogs and cats, covering infections of the respiratory tract, urinary tract, skin and soft tissues, sensory organs, and reproductive system.
Canine Bacterial Respiratory Tract Infections
Respiratory tract infections are highly prevalent infectious diseases in dogs. It ranks among the first-line therapies for canine bacterial respiratory disorders, principally targeting canine infectious tracheobronchitis (kennel cough) and bronchopneumonia caused by pathogens including Pasteurella spp., Bordetella bronchiseptica, Escherichia coli and Staphylococcus spp.
Kennel cough, or canine infectious tracheobronchitis, spreads rapidly among young dogs and group-housed kennel animals. Affected dogs present with paroxysmal dry cough, pharyngalgia and tracheal rales. Without timely intervention, descending secondary infection readily progresses to pneumonia. The product is rapidly absorbed across respiratory mucosa and achieves high concentrations in tracheal, bronchial and pulmonary tissues, efficiently eliminating pathogenic flora and quickly alleviating cough, inflammatory oedema and associated signs.
Canine bronchopneumonia usually arises from ascending upper respiratory bacterial infection, environmental stress and compromised immunity. Clinical signs include depression, pyrexia, productive cough, dyspnoea and pulmonary crackles; severe cases develop pulmonary congestion and consolidation. Clinical data confirm strong bactericidal activity of the product against the polymicrobial pathogens of canine bronchopneumonia. Superior to older antibacterials in tissue penetration, it crosses inflammatory pulmonary barriers to eradicate bacteria in deep lung lesions, markedly reducing deterioration and relapse risk. It is suitable for bacterial bronchopneumonia across all age groups, especially refractory respiratory infections poorly responsive to conventional antibiotics.
Canine Bacterial Urinary Tract Infections
Canine urinary tract infections mostly result from ascending bacterial invasion, with cystitis and pyelonephritis as the most common manifestations. The predominant pathogens are Gram-negative organisms such as E. coli, Proteus spp. and Klebsiella spp., against which it exhibits excellent susceptibility; therefore the product is a dedicated treatment for canine urinary tract infection.
Dogs with cystitis show pollakiuria, stranguria, dysuria, turbid urine and haematuria, together with mucosal congestion, erosion and purulent exudation.
Persistent infection may ascend to the kidneys and cause pyelonephritis, presenting with fever, lumbar pain, depression and anorexia, and potentially irreversible renal injury in severe cases.
Following oral or topical administration, it is renally excreted and concentrates heavily in urine and urinary tissues, attaining concentrations well above minimum inhibitory concentrations to target lesions in the bladder and renal pelvic mucosa and eliminate pathogens completely.
The drug is minimally irritant to urinary mucosa and does not worsen mucosal damage. It rapidly resolves urinary inflammation, corrects micturition abnormalities and blocks ascending spread and recurrence, supporting full-course management of acute and chronic canine bacterial urinary tract infections.
Canine Bacterial Skin and Soft-Tissue Infections
Skin and soft-tissue infections are among the most frequent presentations in small-animal clinics, including pyoderma, wound infection, abscess and folliculitis, commonly caused by Staphylococcus aureus, Streptococcus spp.
And Pasteurella spp. It serves as a core therapy for these conditions due to its broad-spectrum activity and local anti-inflammatory properties.
Canine pyoderma is classified as superficial or deep. Superficial pyoderma presents with erythema, papules, pustules and scaling, whereas deep pyoderma progresses to ulceration, exudation, crusting and subcutaneous swelling, often with a protracted, relapsing course.
For traumatic wound infection, postoperative surgical-site inflammation, subcutaneous abscess and bacterial folliculitis, local or systemic administration of the product establishes effective tissue levels in skin and subcutaneous compartments.
It rapidly suppresses bacterial proliferation and resolves inflammatory signs including swelling, suppuration, pain and exudation, facilitating wound healing. Compared with alternative bactericidal liquids, it sustains longer bactericidal activity and reduces relapse risk, covering primary and secondary bacterial skin and soft-tissue infections in dogs.
Other Canine Bacterial Infections
Beyond the major syndromes above, it is indicated for bacterial otitis media, periodontal infection and prostatitis in dogs.
Canine periodontal infection usually follows oral dysbiosis and dental calculus, manifesting as gingival erythema, bleeding, periodontal suppuration and halitosis. The drug selectively eradicates periodontal pathogens and reduces oral inflammation.
Canine bacterial prostatitis mainly affects intact adult male dogs and typically stems from ascending infection by E. coli and staphylococci. Affected dogs develop dysuria, perineal swelling and depression, and systemic sepsis may ensue without treatment. Systemic it achieves high concentrations in prostatic tissue for effective control of bacterial prostatitis and prevention of systemic complications from disseminated infection.
Marbofloxacin liquid is an animal specific fluoroquinolone antibiotic with a wide spectrum and strong bactericidal activity, widely used in veterinary clinical practice.
(I) Synthesis of the Core Scaffold
The synthesis begins with 2,4-difluoroaniline as starting material. First, electrophilic substitution with sulfuryl chloride introduces sulfur at a defined position on the benzene ring to yield a 2,4-difluorophenylthio intermediate.
The intermediate undergoes diazotisation with sodium nitrite and hydrochloric acid to form a diazonium salt, followed by intramolecular cyclisation to construct the benzothiadiazine core and produce the 3-methyl-9-fluoro-7-oxobenzothiadiazine carboxylate precursor.
This cyclisation is a critical step: temperature must be tightly controlled at 0–5 °C under weakly acidic conditions to minimise side reactions, preserve scaffold integrity and enable subsequent functionalisation.
(II) Functionalisation and Substitution Reactions
After core assembly, the ester group of the intermediate is hydrolysed to a carboxylic acid, giving a benzothiadiazine carboxylic acid intermediate. A nucleophilic substitution reaction introduces 4-methylpiperazine at the C10 position of the scaffold.
The reaction is carried out in anhydrous ethanol under heating and reflux, with an alkaline catalyst to modulate rate, improve conversion and reduce by-products.
After vacuum distillation and recrystallisation, crude marbofloxacin is obtained. Further purification via acid-base treatment, water washing and low-temperature drying yields the API with purity ≥98.5%.
(III) Liquid Formulation Manufacturing
The liquid is formulated from high-purity the API with excipients including water for injection, propylene glycol and buffer salts. Precise blending produces a stable liquid system.
Buffer salts are dissolved in purified water to adjust pH to 5.5–7.0 for chemical stability. Propylene glycol is added to enhance API solubility, and it is introduced slowly under low-temperature stirring until complete dissolution.
Appropriate preservatives and stabilisers are incorporated under continuous homogenisation. The bulk solution is double-filtered through a 0.22 μm sterile membrane, filled and sealed to produce finished product.
This process limits drug degradation, preserves consistent bactericidal activity and meets veterinary pharmaceutical quality standards.
FAQ
Is it a broad spectrum antibiotic?
+
-
Comment: Marbofloxacin is a fluoroquinolone antibacterial compound, with broad-spectrum activity against both Gram-positive and Gram-negative bacteria.
Is it safe for humans?
+
-
Fluoroquinolones, including marbofloxacin, can also increase sensitivity to sunlight. Direct or prolonged sun exposure should be avoided for any animals on this medication. This medication is not intended for use in humans.
Is Marbocyl a strong antibiotic?
+
-
Marbofloxacin is a strong antibiotic, so it should not be given to small- and medium-breed dogs younger than 8 months of age, large-breed dogs younger than 12 months of age, or giant-breed dogs younger than 18 months of age. It should also be avoided in cats less than one year of age.
What drugs interact with it?
+
-
Give at least 2 hours before or after medications containing calcium, antacids, iron, magnesium, or aluminum (such as sucralfate, Tums®, Pepto-Bismol®, or iron supplements). The contents of these medications decrease marbofloxacin absorption.
Does it treat E. coli?
+
-
coli and P. multocida, using efficacy indices: Cmax /MIC and AUC0-24hr /MIC, suggested that IM administration of MBF at a dose of 2 mg kg-1 day-1 is appropriate to treat infections caused by E. coli. However, a dose of 5 mg kg-1 day-1 is recommended to treat pneumonia caused by P.
Hot Tags: marbofloxacin liquid, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Hydrocortisone Powder CAS 50 23 7, tetracaine hcl, Camptothecin Powder CAS 7689 03 4, Primidone powder, Tetracaine hydrochloride powder, 18 Glycyrrhetinic Acid CAS 471 53 4